Compare AbbVie Inc (ABBV) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs VanEck Gold Miners ETF — how do they compare? AbbVie Inc trades at $285.64 (market cap $503.96B), while VanEck Gold Miners ETF trades at $80.2 (market cap $25.18B). The key difference: AbbVie Inc is far larger — about 20× VanEck Gold Miners ETF's market cap, and AbbVie Inc pays a 2.43% dividend while VanEck Gold Miners ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold AbbVie Inc for 93 Days and VanEck Gold Miners ETF for 78 Days on average.
| ABBV | GDX | |
|---|---|---|
Market Cap | $503.96B | $25.18B |
Volume | 5,849,111 | 32,367,822 |
Sector | Health | — |
52-Week High | $289.00 | $115.84 |
52-Week Low | $197.38 | $68.28 |
Typical Hold Time | 93 Days | 78 Days |
Enterprise Value | $568.22B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $284.89, up 0.06% on the day, with strong technical momentum indicated by bullish moving averages and key resistance at $286. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $3.65 vs. $3.61, and revenue growth accelerating to $61.16B in 2025. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity support investor confidence.
Outlook remains positive with analyst consensus price target of $294 offering ~3% upside, though high P/E of 80.56 and patent cliff risks in the 2030s warrant caution. Revenue growth driven by Skyrizi and Rinvoq offsets Humira declines, positioning AbbVie for sustained expansion with 72.7% of analysts maintaining Buy ratings.
GDX (VanEck Gold Miners ETF) is trading at $81.69, down 5.76% with a bearish technical outlook. The ETF faces pressure from declining gold prices and rising interest rates, with moving averages signaling continued weakness. Recent institutional selling activity and mixed analyst sentiment reflect uncertainty in the gold mining sector despite some viewing current levels as attractive for long-term positioning.
The outlook remains challenged by macroeconomic headwinds, though oversold conditions suggest potential for near-term bounce. Key risks include gold price volatility and interest rate sensitivity, while opportunities exist for investors betting on gold's long-term inflation hedge properties at discounted valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
